AC Immune’s (ACIU) Buy Rating Reiterated at BTIG Research

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $8.00 price target on the stock. BTIG Research’s price target suggests a potential upside of 194.66% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reissued a “buy” rating on shares of AC Immune in a research report on Monday, August 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of AC Immune in a report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $7.50.

AC Immune Trading Down 4.1%

Shares of AC Immune stock traded down $0.12 on Wednesday, reaching $2.72. 186,070 shares of the company were exchanged, compared to its average volume of 274,434. The company has a current ratio of 0.93, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. AC Immune has a fifty-two week low of $2.10 and a fifty-two week high of $4.00. The stock has a fifty day moving average price of $2.55 and a 200-day moving average price of $2.68. The firm has a market capitalization of $276.31 million, a price-to-earnings ratio of -5.05 and a beta of 1.60.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Thursday, August 6th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. The firm had revenue of $18.67 million for the quarter, compared to the consensus estimate of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. On average, analysts expect that AC Immune will post -0.6 EPS for the current year.

Institutional Investors Weigh In On AC Immune

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. AXQ Capital LP bought a new position in AC Immune in the 2nd quarter worth approximately $25,000. Arrowstreet Capital Limited Partnership boosted its stake in AC Immune by 8.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after acquiring an additional 30,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of AC Immune by 82.8% in the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after buying an additional 176,701 shares in the last quarter. Institutional investors own 51.36% of the company’s stock.

AC Immune News Roundup

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: Part 1 of the VacSYn Phase 2 trial met all primary safety and immunogenicity endpoints through week 100. ACI-7104 was generally safe and well tolerated, produced a 100% antibody response after three immunizations, and showed antibody penetration into cerebrospinal fluid along with signals of target engagement. AC Immune Phase 2 trial announcement
• Positive Sentiment: The results strengthen investor confidence in AC Immune’s approach to targeting alpha-synuclein, a protein associated with Parkinson’s disease, and provide support for advancing ACI-7104 toward later-stage development. AC Immune durable immunogenicity report
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set an $8 price target, while H.C. Wainwright maintained its Buy rating and $12 target. The targets imply substantial upside from the stock’s recent trading level and signal continued analyst optimism. H.C. Wainwright AC Immune rating
• Neutral Sentiment: Part 1 primarily evaluated safety and immune response. Part 2 is intended to assess clinical activity and determine whether ACI-7104 should advance to Phase 3; discussions with the FDA are expected in early 2027. AC Immune Parkinson’s vaccine results
• Negative Sentiment: Despite the favorable data and analyst support, the stock is trading lower, suggesting investors may be taking profits after the initial trial-driven rally or waiting for evidence of meaningful clinical benefit. The absence of Phase 2 efficacy results remains a key risk.

About AC Immune

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.